⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8814797 | 1.00 | — | — | |
| SCHEMBL61052 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL28348104 | 0.98 | LTA4H (0.37) | — | |
| Hydrochloric Acid SCHEMBL938410 | 0.98 | LTA4H (0.37) | — | |
| Hydrochloric Acid SCHEMBL11344095 | 0.98 | LTA4H (0.37) | — | |
| SCHEMBL11776470 | 0.87 | SMN1; SMN2 (0.42) | — | |
| SCHEMBL24075464 | 0.86 | CA1 (0.39) | — | |
| SCHEMBL12534327 | 0.86 | CA1 (0.39) | — | |
| SCHEMBL930523 | 0.85 | ZDHHC7 (0.40) | — | |
| SCHEMBL930524 | 0.85 | ZDHHC7 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1186332-C | Novel thyroid receptor ligands and method II | KAROBIO AB (SE) | 2005-01-26 | — | — | CN | claimed |
| CN-1337953-A | Novel thyroid receptor ligands and method II | KAROBIO AB (SE) | 2002-02-27 | — | — | CN | claimed |
| US-20250382380-A1 | D-DOMAIN CONTAINING POLYPEPTIDES AND USES THEREOF | ARCELLX INC (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250353908-A1 | D-DOMAIN CONTAINING POLYPEPTIDES AND USES THEREOF | ARCELLX INC (US) | 2025-11-20 | — | — | US | disclosed |
| US-20250320271-A1 | D-DOMAIN CONTAINING POLYPEPTIDES AND USES THEREOF | ARCELLX INC (US) | 2025-10-16 | — | — | US | disclosed |
| EP-4626912-A2 | D-DOMAIN CONTAINING POLYPEPTIDES AND USES THEREOF | Arcellx, Inc. (US) | 2025-10-08 | — | — | EP | disclosed |
| US-12421291-B2 | D-domain containing polypeptides and uses thereof | ARCELLX, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| EP-4600353-A2 | D-DOMAIN CONTAINING POLYPEPTIDES AND USES THEREOF | Arcellx, Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| EP-3710067-B1 | D-DOMAIN CONTAINING POLYPEPTIDES AND USES THEREOF | ARCELLX INC (US) | 2025-07-02 | — | — | EP | disclosed |
| US-12338294-B2 | D-domain containing polypeptides and uses thereof | ARCELLX, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| US-20250154224-A1 | D-DOMAIN CONTAINING POLYPEPTIDES AND USES THEREOF | ARCELLX, INC. | 2025-05-15 | — | — | US | disclosed |
| WO-2006022935-A1 | SOLUBLE AMIDE & ESTER PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2006-03-02 | — | — | WO | disclosed |
| US-20060040954-A1 | Soluble amide & ester pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2006-02-23 | — | — | US | disclosed |
| EP-1599096-A2 | HETERO SUBSTITUED SODIUM CHANNEL BLOCKERS | Parion Sciences, Inc. (US) | 2005-11-30 | — | — | EP | disclosed |
| CN-1186332-C | Novel thyroid receptor ligands and method II | KAROBIO AB (SE) | 2005-01-26 | — | — | CN | disclosed |
| WO-2004073629-A2 | HETERO SUBSTITUED SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2004-09-02 | — | — | WO | disclosed |
| CN-1401621-A | Intermediate for preparing tricyclic compound and preparation method of intermediate | HOECHST MARION ROUSSEL INC (FR) | 2003-03-12 | — | — | CN | disclosed |
| CN-1090178-C | Tricyclic compounds having activity specific for integrins, in particular alpha v beta 3 integrins, process and intermediates for their preparation, their use as medicaments and pharmaceutical compositions containing them | HOECHST MARION ROUSSEL INC (FR) | 2002-09-04 | — | — | CN | disclosed |
| CN-1337953-A | Novel thyroid receptor ligands and method II | KAROBIO AB (SE) | 2002-02-27 | — | — | CN | disclosed |
| CN-1219165-A | Tricyclic compounds having activity specific for integrins, in particular alpha v beta 3 integrins, process and intermediates for their preparation, their use as medicaments and pharmaceutical compositions containing them | HOECHST MARION ROUSSEL CO (FR) | 1999-06-09 | — | — | CN | disclosed |